Guidant's Origin CABG stabilizer/occluder in beta-site testing after 510(k) clearance.
This article was originally published in The Gray Sheet
Executive Summary
GUIDANT's ORIGIN CARDIAC STABILIZER/OCCLUDER IN BETA SITE TESTING at between six and 12 institutions in the U.S. following FDA 510(k) clearance on Aug. 19. Guidant's Origin Medsytems division is conducting the studies to obtain feedback on product design and to determine whether it will sell the dual-use tool -- which is intended for use in coronary artery bypass grafting (CABG) procedures performed on a beating heart -- as a fully disposable product or offer the stabilizing component as a reusable device and the occluding feature as a disposable. The company expects to launch the stabilizer/occluder in early 1998.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.